Rocket Pharmaceuticals Faces Class Action Amid Safety Concerns

Author: Addison Perry Updated: 07-17-2025 08:44 AM

Class Action Investigation of Rocket Pharmaceuticals

In recent developments, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is facing scrutiny as a class action lawsuit has been initiated concerning potential violations of federal securities laws. The law firm Berger Montague PC, committed to investor protection, has stepped forward to investigate claims that allegations surfaced regarding concealed safety issues in relation to the company’s RP-A501 clinical trial.

About Rocket Pharmaceuticals

Headquartered in New Jersey, Rocket Pharmaceuticals is at the forefront of innovative research and clinical programs in genetic medicine. The company focuses on developing transformative therapies aimed at life-threatening genetic diseases.

Allegations of Concealment

The crux of the lawsuit revolves around the introduction of a novel immunomodulatory agent into the RP-A501 trial. Allegations assert that this crucial information was not communicated to shareholders prior to a tragic incident involving a patient, resulting in a fatal adverse event. Following this, an FDA clinical hold was announced, leading to a staggering 37% decline in stock price within just two trading days.

Eligibility to Join the Class Action

Individuals who invested in Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may qualify to join this class action. The critical deadline for filing as a lead plaintiff is set for August 11, 2025. It is essential for investors to explore their rights and consider their options during this investigation.

Legal Support and Resources

Berger Montague, established in 1970, has long operated as a stalwart in securities class action litigation. With offices across several major U.S. cities, this firm has successfully represented both individual and institutional investors over the past five decades. Their extensive experience makes them uniquely positioned to guide affected investors through this tumultuous period.

How to Reach Out

Individuals seeking more clarity on their rights or any further information can connect with:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com

Frequently Asked Questions

What is the reason behind the class action against Rocket Pharmaceuticals?

The class action is initiated due to allegations that Rocket Pharmaceuticals concealed safety data regarding its RP-A501 trial, which may have negatively impacted investors.

Who is eligible to participate in the class action?

Investors who purchased Rocket Pharmaceuticals stocks between February 27, 2025, and May 26, 2025, can join the class action.

What is the deadline for filing as a lead plaintiff?

The deadline for filing as a lead plaintiff in the lawsuit is August 11, 2025.

How can I contact the firm handling the case?

You can reach Berger Montague at their Philadelphia office, or contact Andrew Abramowitz or Caitlin Adorni directly via phone or email.

What are the potential outcomes of the class action?

Depending on the investigation’s outcome, affected investors may receive compensation for their losses if the court rules in favor of the plaintiffs.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.